S&P 500   2,789.82 (+1.45%)
DOW   23,719.37 (+1.22%)
QQQ   200.86 (+0.14%)
AAPL   267.99 (+0.72%)
FB   175.19 (+0.52%)
MSFT   165.14 (+0.01%)
GOOGL   1,206.57 (-0.04%)
AMZN   2,042.76 (-0.01%)
CGC   14.57 (-1.75%)
NVDA   262.86 (-1.53%)
BABA   196.37 (+0.20%)
MU   46.13 (-4.47%)
GE   7.14 (-2.19%)
TSLA   573.00 (+4.40%)
AMD   48.38 (-0.84%)
T   30.73 (+2.81%)
ACB   0.88 (+2.34%)
F   5.37 (+6.76%)
NFLX   370.81 (-0.08%)
BAC   24.86 (+6.01%)
GILD   73.51 (-1.97%)
DIS   104.50 (+3.39%)
PRI   102.14 (+4.75%)
S&P 500   2,789.82 (+1.45%)
DOW   23,719.37 (+1.22%)
QQQ   200.86 (+0.14%)
AAPL   267.99 (+0.72%)
FB   175.19 (+0.52%)
MSFT   165.14 (+0.01%)
GOOGL   1,206.57 (-0.04%)
AMZN   2,042.76 (-0.01%)
CGC   14.57 (-1.75%)
NVDA   262.86 (-1.53%)
BABA   196.37 (+0.20%)
MU   46.13 (-4.47%)
GE   7.14 (-2.19%)
TSLA   573.00 (+4.40%)
AMD   48.38 (-0.84%)
T   30.73 (+2.81%)
ACB   0.88 (+2.34%)
F   5.37 (+6.76%)
NFLX   370.81 (-0.08%)
BAC   24.86 (+6.01%)
GILD   73.51 (-1.97%)
DIS   104.50 (+3.39%)
PRI   102.14 (+4.75%)
S&P 500   2,789.82 (+1.45%)
DOW   23,719.37 (+1.22%)
QQQ   200.86 (+0.14%)
AAPL   267.99 (+0.72%)
FB   175.19 (+0.52%)
MSFT   165.14 (+0.01%)
GOOGL   1,206.57 (-0.04%)
AMZN   2,042.76 (-0.01%)
CGC   14.57 (-1.75%)
NVDA   262.86 (-1.53%)
BABA   196.37 (+0.20%)
MU   46.13 (-4.47%)
GE   7.14 (-2.19%)
TSLA   573.00 (+4.40%)
AMD   48.38 (-0.84%)
T   30.73 (+2.81%)
ACB   0.88 (+2.34%)
F   5.37 (+6.76%)
NFLX   370.81 (-0.08%)
BAC   24.86 (+6.01%)
GILD   73.51 (-1.97%)
DIS   104.50 (+3.39%)
PRI   102.14 (+4.75%)
S&P 500   2,789.82 (+1.45%)
DOW   23,719.37 (+1.22%)
QQQ   200.86 (+0.14%)
AAPL   267.99 (+0.72%)
FB   175.19 (+0.52%)
MSFT   165.14 (+0.01%)
GOOGL   1,206.57 (-0.04%)
AMZN   2,042.76 (-0.01%)
CGC   14.57 (-1.75%)
NVDA   262.86 (-1.53%)
BABA   196.37 (+0.20%)
MU   46.13 (-4.47%)
GE   7.14 (-2.19%)
TSLA   573.00 (+4.40%)
AMD   48.38 (-0.84%)
T   30.73 (+2.81%)
ACB   0.88 (+2.34%)
F   5.37 (+6.76%)
NFLX   370.81 (-0.08%)
BAC   24.86 (+6.01%)
GILD   73.51 (-1.97%)
DIS   104.50 (+3.39%)
PRI   102.14 (+4.75%)
Log in

NASDAQ:ACERAcer Therapeutics Stock Price, Forecast & News

$1.97
-0.10 (-4.83 %)
(As of 04/9/2020 04:00 PM ET)
Add
Compare
Today's Range
$1.92
Now: $1.97
$2.14
50-Day Range
$1.18
MA: $2.89
$5.86
52-Week Range
$1.08
Now: $1.97
$28.25
Volume68,600 shs
Average Volume82,514 shs
Market Capitalization$19.89 million
P/E RatioN/A
Dividend YieldN/A
Beta1.8
Acer Therapeutics Inc., a pharmaceutical company, focuses on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases. Its pipeline includes three clinical-stage candidates: EDSIVO for the treatment of vascular Ehlers-Danlos Syndrome in patients with a confirmed type III collagen mutation; and ACER-001, a formulation of sodium phenylbutyrate for the treatment of various inborn errors of metabolism, including urea cycle disorders, maple syrup urine disease, and osanetant for the treatment of various neuroendocrine disorders. The company was founded in 2013 and is headquartered in Newton, Massachusetts.
Read More
Acer Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.2Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.18 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ACER
CUSIPN/A
Phone844-902-6100

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$1.82 per share

Profitability

Net Income$-29,420,000.00

Miscellaneous

Employees23
Market Cap$19.89 million
Next Earnings Date5/12/2020 (Estimated)
OptionableNot Optionable

Receive ACER News and Ratings via Email

Sign-up to receive the latest news and ratings for ACER and its competitors with MarketBeat's FREE daily newsletter.


Acer Therapeutics (NASDAQ:ACER) Frequently Asked Questions

How has Acer Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Acer Therapeutics' stock was trading at $3.38 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, ACER shares have decreased by 41.7% and is now trading at $1.97. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Acer Therapeutics?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Acer Therapeutics in the last year. There are currently 3 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Acer Therapeutics.

When is Acer Therapeutics' next earnings date?

Acer Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, May 12th 2020. View our earnings forecast for Acer Therapeutics.

How were Acer Therapeutics' earnings last quarter?

Acer Therapeutics Inc (NASDAQ:ACER) issued its quarterly earnings results on Wednesday, March, 18th. The biopharmaceutical company reported ($0.51) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.48) by $0.03. View Acer Therapeutics' earnings history.

What price target have analysts set for ACER?

5 brokerages have issued 12 month price objectives for Acer Therapeutics' shares. Their forecasts range from $9.00 to $48.00. On average, they anticipate Acer Therapeutics' share price to reach $22.33 in the next year. This suggests a possible upside of 1,033.7% from the stock's current price. View analysts' price targets for Acer Therapeutics.

Has Acer Therapeutics been receiving favorable news coverage?

Headlines about ACER stock have been trending very negative on Thursday, according to InfoTrie Sentiment. The research group identifies positive and negative news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Acer Therapeutics earned a daily sentiment score of -3.3 on InfoTrie's scale. They also gave media coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the near term. View the latest news aboutAcer Therapeutics.

Who are some of Acer Therapeutics' key competitors?

What other stocks do shareholders of Acer Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Acer Therapeutics investors own include Sarepta Therapeutics (SRPT), Amarin (AMRN), Advanced Micro Devices (AMD), Novavax (NVAX), Synergy Pharmaceuticals (SGYP), NovaBay Pharmaceuticals (NBY), NVIDIA (NVDA), Anavex Life Sciences (AVXL), Arena Pharmaceuticals (ARNA) and Exelixis (EXEL).

Who are Acer Therapeutics' key executives?

Acer Therapeutics' management team includes the following people:
  • Mr. Christopher Schelling, Founder, Pres, CEO & Director (Age 43)
  • Mr. Harry S. Palmin, COO & CFO (Age 49)
  • Dr. William T. Andrews M.D., FACP, Chief Medical Officer (Age 54)
  • Mr. Donald R. Joseph, Chief Legal Officer & Sec. (Age 65)
  • Ms. Jeannie Kim, VP of Corp. Devel.

What is Acer Therapeutics' stock symbol?

Acer Therapeutics trades on the NASDAQ under the ticker symbol "ACER."

How do I buy shares of Acer Therapeutics?

Shares of ACER can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Acer Therapeutics' stock price today?

One share of ACER stock can currently be purchased for approximately $1.97.

How big of a company is Acer Therapeutics?

Acer Therapeutics has a market capitalization of $19.89 million. The biopharmaceutical company earns $-29,420,000.00 in net income (profit) each year or ($2.91) on an earnings per share basis. Acer Therapeutics employs 23 workers across the globe. View additional information about Acer Therapeutics.

What is Acer Therapeutics' official website?

The official website for Acer Therapeutics is http://www.acertx.com/.

How can I contact Acer Therapeutics?

Acer Therapeutics' mailing address is 300 WASHINGTON STREET SUITE 351, NEWTON MA, 02458. The biopharmaceutical company can be reached via phone at 844-902-6100 or via email at [email protected]

This page was last updated on 4/9/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel